GlassScriptPhysician profile
Paul Cohen
NPI 1194778423
$621.82
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2021: $287 · 2022: $47.78 · 2023: $70.68 · 2024: $77.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $131.67 | 2021-2023 | Trelegy Ellipta |
| Inari Medical, INC. | $118.79 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $109.47 | 2019 | |
| Abbvie INC. | $65.31 | 2022-2023 | Vraylar |
| Amgen INC. | $32.15 | 2024 | Krystexxa |
| Mylan Specialty L.P. | $28.79 | 2019 | |
| Novo Nordisk INC | $23.57 | 2024 | Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.49 | 2023 | Xifaxan |
| Amarin Pharma, INC. | $22.21 | 2021 | |
| Abbott Laboratories | $21.96 | 2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $16.08 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $16.07 | 2021 | |
| Pfizer INC. | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.